Appoints Leena Gandhi, MD, PhD, as Chief Medical Officer

$80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures Advance Novel Immuno-Oncology Programs

NextPoint Therapeutics Presents Poster on NPX267 at 37th SITC Annual Meeting in Boston, MA

Neomorph Report: Molecular glue CELMoD compounds are regulators
of cereblon conformation

Sanofi backs $100M round for startup targeting immune system diseases

Matchpoint: a toolkit to create covalent therapies for immunology

Timmerman Report: Matchpoint gets $100 Million to Take Covalent Binders in Autoimmune Disease

Boston Business Journal: Sanofi backs $100M round for startup targeting immune system diseases

Biospace: Sanofi-Backed Matchpoint Launches with $100M for Precision Covalent Medicines - Updated

Neomorph, Inc. Announces Appointment of Chief Financial Officer

Guggenheim Healthcare Talks – Targeted Protein Degradation Day

Neomorph, Inc. to Participate in Upcoming Guggenheim Healthcare Talks – Targeted Protein Degradation Day

Philip Chamberlain Named as Chief Executive Officer of Neomorph

Dana-Farber Cancer Institute launches investment fund to support startup companies

Neomorph, Inc. Announces $109 Million Series A Financing to Advance Proprietary Protein Degradation Platform and Programs

Neomorph: Annual Review of Cancer Biology Small-Molecule Approaches to Targeted Protein Degradation